Medically reviewed by Erik Natkin, DO — Founder, R2 Medical Clinic, Denver, Colorado
Last medically reviewed: September 2026

Peptide therapy has become increasingly popular.

Unfortunately, the regulatory environment surrounding peptides has also become increasingly confusing.

Patients may encounter peptides through an FDA-approved medication, a traditional compounding pharmacy, an outsourcing facility, a telemedicine clinic, or a website selling products labeled “research use only.”

These products are not necessarily regulated in the same way.

Even more confusing, the regulatory status of a particular peptide may change as the U.S. Food and Drug Administration evaluates new information.

Understanding peptide regulation therefore requires answering several separate questions:

Is the peptide part of an FDA-approved drug?
Is it being compounded?
Is it being compounded by a 503A pharmacy or 503B outsourcing facility?
Is the active ingredient permitted for use in compounding?
Is the product being prescribed for an individual patient?
Is it being sold as a medication or as a “research” product?
Is an appropriately licensed healthcare professional supervising treatment?

The fact that something is called a peptide tells us very little about its regulatory status.

First: What Is a Peptide?

Peptides are short chains of amino acids.

The human body naturally produces many peptides that function as signaling molecules involved in processes such as:

Hormonal signaling
Appetite and satiety
Metabolism
Growth
Reproduction
Gastrointestinal function
Immune signaling
Numerous other physiologic processes

Peptide-based medications are not inherently experimental. Several FDA-approved medications are peptides or peptide-related drugs.

Amino acid molecular structure zoomed from a peptide chain, alongside a translucent human body highlighting the brain, digestive tract, metabolism, immune, reproductive and joint systems that peptides help signal

At the same time, many peptides promoted online have never received FDA approval for the uses for which they are being marketed.

This creates one of the most important distinctions in peptide medicine:

“Peptide” is a chemical or biological description—not a regulatory category.

Category 1: FDA-Approved Peptide Medications

The clearest regulatory pathway is an FDA-approved drug.

Before approving a new drug, FDA evaluates evidence regarding its safety, effectiveness, manufacturing and quality for specific indications.

FDA approval also establishes requirements involving manufacturing, labeling and ongoing regulatory oversight.

This does not mean an FDA-approved medication is risk-free. It means the medication has gone through the FDA drug-approval process.

That is fundamentally different from a compounded medication.

Category 2: Compounded Peptide Medications

Compounding allows a pharmacist or physician, under specific circumstances, to prepare a medication for a patient’s medical needs.

Compounding can play an important role when an FDA-approved medication does not appropriately meet a patient’s needs.

But there is an essential distinction:

Compounded drugs are not FDA-approved drugs.

FDA does not individually evaluate compounded medications for safety, effectiveness and quality before they are dispensed in the same manner that it evaluates FDA-approved medications.

This remains true even when the medication is legitimately prescribed and prepared by a licensed compounding pharmacy.

Two major sections of federal law govern much of human drug compounding: Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act.

They are not interchangeable.

What Is a 503A Compounding Pharmacy?

503A represents what most patients traditionally think of as a compounding pharmacy.

In general, medication is compounded for an identified individual patient pursuant to a valid prescription.

503A compounding may be performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician when the applicable statutory requirements are satisfied.

State boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities. FDA still has regulatory and enforcement authority and may conduct inspections.

This means describing a 503A pharmacy simply as an “FDA-approved pharmacy” would be inaccurate.

A better description is: a state-licensed pharmacy operating within a federal and state regulatory framework for pharmacy compounding.

What Is a 503B Outsourcing Facility?

503B created a different category known as an outsourcing facility.

A 503B facility registers with FDA and is subject to a different regulatory framework.

Unlike traditional 503A compounding, a 503B outsourcing facility can compound certain medications without first receiving prescriptions for individually identified patients.

503B outsourcing facilities are also subject to FDA current Good Manufacturing Practice requirements and FDA inspection according to a risk-based schedule. This makes 503B different from 503A.

But there is another important point: 503B does not mean FDA-approved.

A compounded medication produced by a 503B outsourcing facility is still not the same thing as an FDA-approved drug.

503A vs. 503B: A Simple Way to Think About It

Although the complete regulations are considerably more complicated, patients can think about the distinction this way:

Comparison of an FDA-approved drug, a 503A compounded medication, a 503B compounded medication and an online research peptide showing checklists of what each pathway does and does not involve, captioned different pathways, not equivalent

FDA-approved drug: FDA has reviewed and approved the drug for specific indications and regulates its manufacturing and labeling.
503A compounded medication: Generally compounded for an identified individual patient pursuant to a prescription through a traditional pharmacy-compounding framework.

503B compounded medication: Produced by an FDA-registered outsourcing facility operating under additional federal manufacturing requirements.
Online “research peptide”: May be sold outside the traditional prescription and pharmacy system and may explicitly state that it is “not for human consumption.”

These categories should not be treated as equivalent simply because the vial contains—or claims to contain—the same peptide.

Can a 503A Pharmacy Compound Any Peptide a Physician Prescribes?

No.

This is one of the most misunderstood areas of peptide therapy. A physician writing a prescription does not automatically make a peptide eligible for legal compounding.

Federal law places restrictions on which bulk drug substances may be used in 503A compounding.

In general, a bulk substance used for 503A compounding must satisfy an applicable USP or National Formulary monograph when one exists, be a component of an FDA-approved drug when the applicable conditions are met, or appear on FDA’s 503A Bulks List.

There are additional requirements as well. For example, the bulk substance must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA as required under federal law.

This is an important distinction between legitimate pharmaceutical compounding and simply purchasing peptide powder from an internet supplier.

Then Why Are Some Other Peptides Still Being Compounded?

This is where the regulatory environment becomes more complicated.

FDA has been evaluating substances that have been nominated for inclusion on the 503A Bulks List. During this process, FDA established an interim enforcement policy for certain nominated substances.

Historically, FDA divided nominated substances into three categories.

Category 1

These substances were nominated with sufficient information for FDA evaluation and did not appear on another list. Under FDA’s interim policy, the agency generally stated that it did not intend to take enforcement action against 503A compounders solely for using certain Category 1 substances while FDA evaluated them, provided the other conditions of the policy were satisfied.

Category 1 did not mean FDA-approved. It also did not necessarily mean that FDA had concluded the substance was safe or effective. It represented an interim regulatory position while FDA evaluated the substance.

Category 2

Category 2 included substances for which FDA identified potential significant safety risks. These substances did not receive the same interim enforcement approach afforded to Category 1 substances.

Category 3

Category 3 generally involved substances that had been nominated without sufficient supporting information for FDA to evaluate them. They likewise did not receive the Category 1 interim enforcement approach.

An Important 2025–2026 Change

Peptide regulation continues to evolve. FDA revised its interim policy in January 2025.

Under the revised policy, FDA stated that it does not intend to place substances newly nominated on or after January 7, 2025 into Categories 1, 2 or 3. Existing Category 1 substances may continue under the interim policy while FDA evaluates them, unless FDA removes them or otherwise changes their status.

Newer nominations instead proceed through FDA’s statutory evaluation process for possible inclusion on the 503A Bulks List.

This is one reason older internet articles and social-media posts describing a peptide as “Category 1” or “Category 2” may no longer accurately describe its current regulatory status.

2026 Has Already Brought Important Changes

Several peptides commonly discussed in peptide medicine have undergone regulatory changes or further FDA review.

For example, FDA’s April 2026 update removed several substances from previous categories after their nominations were withdrawn. These included substances associated with:

Removal from Category 2, however, should not automatically be interpreted as FDA determining that a substance is safe, effective or approved.

In several instances, FDA indicated that the agency intended to continue evaluating related substances through the Pharmacy Compounding Advisory Committee.

FDA April 2026 update removing BPC-157, Cathelicidin LL-37, Dihexa acetate, Emideltide/DSIP, Epitalon, GHK-Cu, KPV, Melanotan II, MOTS-c, PEG-MGF, Semax and TB-500 from previous categories after nominations were withdrawn, with regulatory status continuing to evolve

BPC-157
Cathelicidin LL-37
Dihexa acetate
Emideltide/DSIP
Epitalon
GHK-Cu

KPV
Melanotan II
MOTS-c
PEG-MGF
Semax
TB-500

That distinction matters. “No longer Category 2” does not mean “FDA-approved.”

FDA’s 2026 Review of Popular Peptides

In July 2026, FDA’s Pharmacy Compounding Advisory Committee considered several peptide-related bulk substances for potential inclusion on the 503A Bulks List. Among the substances reviewed were forms related to:

BPC-157
KPV
TB-500
MOTS-c
Emideltide/DSIP
Semax
Epitalon

The uses considered by FDA varied by substance and included areas such as wound healing, inflammatory conditions, obesity, osteoporosis, insomnia and other proposed indications.

The important point for patients is not simply whether a particular peptide appeared before an FDA committee.

It is that FDA is actively evaluating whether particular bulk substances should be eligible for 503A compounding.

Being discussed by FDA is not the same as being FDA-approved. Being nominated for the 503A Bulks List is not the same as appearing on the final list. And appearing under an interim enforcement policy is not the same as FDA concluding that a treatment is safe and effective.

What Does “Significant Safety Risk” Mean?

FDA has identified potential safety concerns with several substances proposed for compounding.

Peptides can present unique manufacturing and characterization challenges. Depending upon the substance, FDA has raised concerns involving:

Peptide-related impurities
Aggregation
Immunogenicity
Difficulty characterizing the active pharmaceutical ingredient
Limited human safety data
Serious adverse events associated with particular substances or routes of administration

Importantly, the amount of evidence differs from peptide to peptide.

FDA’s identification of a potential risk does not necessarily establish that a particular adverse event was caused by the peptide.

But limited evidence is itself relevant when deciding whether a substance should be administered to patients.

Why Immunogenicity Matters With Peptides

One concern that appears repeatedly in FDA’s discussion of compounded peptides is immunogenicity.

The immune system can recognize certain proteins, peptides, aggregates or impurities as foreign. That can potentially trigger an immune response.

The manufacturing and purification of peptides can also be complicated, and peptide-related impurities may be difficult to characterize completely.

This is one reason pharmaceutical quality matters. A peptide should not be evaluated only by asking:

“Is the molecule supposed to work?”

We also need to ask:

“What exactly is in the finished product?”

What About BPC-157?

BPC-157 illustrates why patients and clinicians should be careful with simplified statements about peptide regulation.

BPC-157 has been widely promoted online for injury recovery and tissue healing.

It previously appeared in FDA’s Category 2 materials following identification of potential safety concerns and limited safety information. Its earlier nomination was subsequently withdrawn, and FDA removed it from Category 2 in its April 2026 update.

FDA then considered BPC-157-related bulk substances—BPC-157 free base and BPC-157 acetate—during the July 2026 Pharmacy Compounding Advisory Committee process.

None of those facts mean BPC-157 has become an FDA-approved drug. They illustrate a broader point:

Regulatory status must be checked currently and for the specific substance and formulation being considered.

“My Pharmacy Compounds It” Does Not Answer Every Regulatory Question

Patients sometimes assume that if a pharmacy is willing to prepare a peptide, the peptide itself must have been approved by FDA. That is not necessarily true.

There are several separate questions:

Is the pharmacy appropriately licensed?
Is the substance eligible for compounding under current federal law and FDA policy?
Is the medication being compounded under 503A or 503B?
Is the particular use supported by adequate clinical evidence?
Is the treatment medically appropriate for this particular patient?

These questions should not be collapsed into one.

What About Peptides Sold Online as “Research Use Only”?

This is another regulatory category entirely.

Websites frequently sell peptide products labeled:

“Research use only.”
“For laboratory use only.”
“Not for human consumption.”

Patients may nevertheless encounter social-media discussions, dosing instructions or other information suggesting that people are injecting these products.

A “research” label does not create a loophole allowing a company to market an unapproved drug for human use.

FDA evaluates products based not simply on isolated disclaimers but on the circumstances surrounding how they are marketed and their intended use.

FDA continues to take enforcement action against companies selling purported research peptides when the agency determines that the products are actually being marketed as unapproved drugs for human use.

FDA Enforcement Against Online Peptide Sellers Is Continuing

This is not merely a historical issue.

In August 2026, FDA issued a warning letter to an online peptide company after reviewing products marketed through its website.

The products included several substances advertised as “research peptides.” FDA concluded that multiple products were being marketed as unapproved new drugs.

The agency specifically highlighted the additional concern associated with injectable products because injection bypasses some of the body’s defenses against microorganisms and toxins.

This illustrates an important principle:

Putting “research use only” on a vial does not necessarily determine how FDA will regulate a product when the surrounding marketing demonstrates intended human use.

A Certificate of Analysis Does Not Change the Regulatory Status

Online peptide companies frequently emphasize:

“99% purity”
“Third-party tested”
“Independent laboratory verified”
Certificates of Analysis

These claims do not turn a research product into an FDA-approved medication. They also do not turn the seller into a licensed pharmacy. And they do not establish that the product is legally appropriate for human administration.

A laboratory report may provide information about the particular sample tested. It does not substitute for the regulatory framework governing medications intended for patients.

Pharmacy Regulation and Medical Practice Are Different Questions

There is another important piece of peptide regulation that is sometimes overlooked. The pharmacy and the healthcare professional have different responsibilities.

Pharmacy law governs issues surrounding compounding, preparation and dispensing. Medical practice is regulated separately, primarily at the state level. A clinician must still practice within applicable licensing requirements and standards of care.

Therefore, even if a particular peptide can legally be compounded, that does not automatically answer whether prescribing it to a particular patient is medically appropriate.

Likewise, a clinician’s willingness to prescribe a substance does not automatically establish that a pharmacy can legally compound it.

Both sides matter.

Why Physician Oversight Still Matters

Regulation establishes boundaries. It does not replace clinical judgment.

Before considering peptide therapy, an appropriate healthcare professional should evaluate questions such as:

Why is the peptide being considered?
What human evidence supports the proposed use?
Is there an FDA-approved therapy that is more appropriate?
What contraindications exist?
What medications might interact with treatment?

What baseline evaluation is appropriate?
What dose and duration are reasonable?
What monitoring is necessary?
What adverse effects should trigger discontinuation?
How will we determine whether treatment is actually working?

That last question is particularly important. Treatment should not become:

Prescribe → inject → refill indefinitely.

There should be a clinical goal and a plan for reassessment.

Considering peptide therapy? R2 Medical Clinic offers physician-led peptide therapy evaluation in Denver, Wheat Ridge/Arvada and Castle Rock, built around an individualized review of regulatory status, evidence and clinical goals.

Schedule a consultation or call (720) 640-2333.

FDA Approval, Legal Compounding and Good Medical Care Are Three Different Things

This may be the most important concept for patients to understand. A peptide can be discussed on three separate levels:

Regulatory status. Is there an FDA-approved drug? If not, is the substance legally eligible for compounding under the applicable circumstances?
Pharmaceutical quality. Where was the medication prepared? What standards and controls apply to the pharmacy or facility?
Clinical appropriateness. Is there sufficient evidence and a reasonable medical rationale for this particular patient?

These questions overlap, but they are not interchangeable.

Something can potentially be lawful to compound without having strong evidence for every use. A treatment can have promising scientific evidence without being legally eligible for compounding. And a well-made medication can still be inappropriate for a particular patient.

Questions Patients Should Ask Before Starting Peptide Therapy

Before starting treatment, consider asking:

Is this an FDA-approved medication or a compounded medication?
If compounded, why is compounding appropriate?
Is this being prepared through a 503A pharmacy or a 503B outsourcing facility?
Is this particular substance currently eligible for compounding?
What human evidence supports using it for my condition or goal?

What are the known risks?
What important risks remain unknown?
What monitoring will I receive?
When will treatment be reassessed?
Where exactly is my medication coming from?

A healthcare professional offering peptide therapy should be comfortable discussing these questions.

The Bottom Line

Peptide regulation cannot accurately be summarized as:

“Peptides are legal.” or: “Peptides are banned.”

Neither statement adequately describes the current regulatory environment.

Some peptide drugs are FDA-approved. Some medications may be appropriately compounded under Sections 503A or 503B when federal requirements are satisfied. Some bulk peptide substances remain under FDA evaluation. Some have raised significant safety concerns. And products sold directly online as “research peptides” may fall entirely outside the legitimate pharmacy dispensing pathway—and labeling something “research use only” does not necessarily prevent FDA from treating it as an unapproved drug when it is marketed for human use.

The regulatory status of an individual peptide therefore needs to be evaluated individually and currently.

But regulation is only part of responsible peptide therapy. Patients should also understand the evidence supporting the treatment, where their medication comes from, why it is being prescribed, what risks are known and unknown, and how their healthcare professional plans to monitor them.

Peptide therapy should begin with appropriate medical care—not with finding a vial online. If you would like an evaluation, schedule a consultation at any of our three Denver-metro locations.

About the Medical Reviewer

Erik Natkin, DO, is the founder of R2 Medical Clinic, a physician-led medical practice serving Denver, Wheat Ridge/Arvada and Castle Rock, Colorado. His clinical practice includes individualized hormone optimization, physician-supervised medical weight management, peptide therapy and other areas of wellness medicine.

This article is intended for general educational purposes and does not constitute individual medical advice, diagnosis or treatment. Compounded medications are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before marketing in the same manner as FDA-approved drugs. Federal and state laws and FDA policies concerning compounding can change. The regulatory status, available evidence, risks and appropriateness of individual peptides should be evaluated individually and currently. Treatment decisions should be made with an appropriately licensed healthcare professional.

Medical References

U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
U.S. Food and Drug Administration. FD&C Act Provisions That Apply to Human Drug Compounding.
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act; Guidance for Industry.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.
U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs.
U.S. Food and Drug Administration. Human Drug Compounding Policies and Rules.